Education
About Us
Working with TipRanks
Follow Us
Vigil Neuroscience, Inc. (VIGL)
:VIGL
VIGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.31 - $6.06
Previous CloseN/A
Volume101.11K
Average Volume (3M)144.08K
Market Cap
$83.54M
Enterprise Value-$14.03M
Total Cash (Recent Filing)$24.15M
Total Debt (Recent Filing)$303.00K
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 07, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding46,671,535
10 Day Avg. Volume117,246
30 Day Avg. Volume144,079
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$15.00Price Target Upside728.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Vigil Neuroscience, Inc. News
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentVG-3927 is viewed as a highly differentiated candidate due to its broader mechanism of action, blood barrier penetration capability, and lack of sink effect.
Partnership PotentialThe likelihood that Vigil Neuroscience strikes a large Alzheimer's disease-focused partnership deal for VG-3927 before the Phase 2 study start is quite high.
Regulatory PathwayFDA had shown interest for a potential accelerated approval pathway for iluzanebart.
Bears Say
Financial PerformanceThe company ended the year with $97.8MM in cash and reiterated guidance for cash runway into 2026.
Market ReactionVigil Neuroscience's shares are trading higher on the news, but the current stock move understates the positivity of the data, suggesting potential for further growth.
Price Target AdjustmentRevisiting operational expense assumptions beyond 2025 reduces the price target to $14 from $17.
---
Ownership Overview
29.07% Insiders
2.78% Mutual Funds
32.83% Other Institutional Investors
33.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VIGL FAQ
What was Vigil Neuroscience, Inc.’s price range in the past 12 months?
Vigil Neuroscience, Inc. lowest stock price was $1.31 and its highest was $6.06 in the past 12 months.
What is Vigil Neuroscience, Inc.’s market cap?
Vigil Neuroscience, Inc.’s market cap is $83.54M.
When is Vigil Neuroscience, Inc.’s upcoming earnings report date?
Vigil Neuroscience, Inc.’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were Vigil Neuroscience, Inc.’s earnings last quarter?
Vigil Neuroscience, Inc. released its earnings results on Mar 13, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.533 by -$0.037.
Is Vigil Neuroscience, Inc. overvalued?
According to Wall Street analysts Vigil Neuroscience, Inc.’s price is currently Undervalued.
Does Vigil Neuroscience, Inc. pay dividends?
Vigil Neuroscience, Inc. does not currently pay dividends.
What is Vigil Neuroscience, Inc.’s EPS estimate?
Vigil Neuroscience, Inc.’s EPS estimate is -0.53.
How many shares outstanding does Vigil Neuroscience, Inc. have?
Vigil Neuroscience, Inc. has 46,671,535 shares outstanding.
What happened to Vigil Neuroscience, Inc.’s price movement after its last earnings report?
Vigil Neuroscience, Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.533. Following the earnings report the stock price went down -10.213%.
Which hedge fund is a major shareholder of Vigil Neuroscience, Inc.?
Currently, no hedge funds are holding shares in VIGL
---
Vigil Neuroscience, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (728.73% Upside)
$15.00 (728.73% Upside)
Blogger Sentiment
Bullish
VIGL Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 338.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.37%
12-Months-Change
Fundamentals
Return on Equity
-89.69%
Trailing 12-Months
Asset Growth
-16.45%
Trailing 12-Months
Company Description
Vigil Neuroscience, Inc.
Vigil Neuroscience Inc (VIGL) is a biotechnology company focused on the development of novel therapeutics for neurodegenerative diseases. Operating within the healthcare and life sciences sectors, the company is dedicated to harnessing the power of microglia, the brain's resident immune cells, to develop innovative treatments aimed at improving the lives of patients suffering from debilitating neurological conditions. Vigil Neuroscience's core products are in various stages of clinical development, targeting diseases with high unmet medical needs.
---
VIGL Stock 12 Month Forecast
Average Price Target
$15.00
▲(728.73% Upside)
Technical Analysis
Achieve Life Sciences
―
Exicure
―
I-MAB
―
Unicycive Therapeutics
―
Caribou Biosciences
―
Best Analysts Covering VIGL
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-40.40%
reiterated a buy rating last month
Copying Paul Matteis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.40% per trade.
---